leadf
logo-loader
viewValiRx PLC

ValiRx updates on JV discussions and switches NOMAD

The company said it also expects to receive a tax credit shortly

ValiRx PLC - ValiRx updates on JV discussions and switches NOMAD
ValiRx is a clinical stage biotechnology company focused on cancer

ValiRx PLC (LON:VAL) said discussions to form a joint venture with investment firm Alpha Blue Ocean have not progressed beyond what it told the market in May and June.

As a result, any deal brokered “will be considered along with other opportunities”.

The update came as the drug developer said Novum was its new nominated adviser after SVS Securities was placed into administration.

ValiRx said it expects to receive a £400,000 R&D tax credit shortly. In the meantime, it continues to carefully manage its working capital position.

Quick facts: ValiRx PLC

Price: 31.89 GBX

AIM:VAL
Market: AIM
Market Cap: £17.87 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

2 min read